Mirum Pharmaceuticals, Inc.
NASDAQ:MIRMBiotechnology
+$3.89 today
- Market cap
- $6.04B
- Beta
- 0.51
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$13.57
Volume 0.50M
Average 0.95M
MIRM Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Mirum Pharmaceuticals, Inc.NASDAQ: MIRM
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $6.94M rose 14.5% year over year, ahead of the +7.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +95.6% a year.
Context
- Depreciation & amortization amounted to 4.7% of revenue in FY2025, down 2.4 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +14.5% holds above the trailing-twelve-month pace of +7.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 24.24M USD
- Year-over-year change
- +2.6%
- 4-year CAGR
- +123.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.24M | +2.6% |
| FY2024 | 2024-12-31 | 23.63M | +118.2% |
| FY2023 | 2023-12-31 | 10.83M | +234.4% |
| FY2022 | 2022-12-31 | 3.24M | +232.1% |
| FY2021 | 2021-12-31 | 975K | — |
Depreciation & Amortization vs competitors
How MIRM compares with its peers on the latest reported figures
- MIRM's LTM Jun 2026 depreciation & amortization of $25.95M is the 2nd largest of the 8 companies compared; the peer median is $4.95M.
- Its year-over-year change of +7.1% is the 2nd highest of 8, against a peer median of -5.7%.
- Depreciation & amortization amounts to 4.2% of revenue for MIRM, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $52.78M | -3.5% | +43.1% | 8.1% | |
| LTM Jun 2026 | $25.95M | +7.1% | +95.6% | 4.2% | |
| LTM Mar 2026 | $13.62M | -61.8% | +24.3% | 2.0% | |
| LTM Mar 2026 | $5.26M | -5.7% | -15.4% | 8.0% | |
| LTM Mar 2026 | $4.95M | +56.5% | +19.6% | 7.2% | |
| LTM Mar 2026 | $2.88M | -16.2% | +25.6% | 6.4% | |
| LTM Jun 2026 | $1.52M | +7.1% | +47.7% | 0.1% | |
| LTM Mar 2026 | $106K | -33.8% | -39.0% | 294.4% | |
| Peer median (excluding MIRM) | $4.95M | -5.7% | +24.3% | 7.2% | |
Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (83.99M) | (135.67M) | (163.42M) | (87.94M) | (23.36M) |
| Depreciation & Amortization | 975K | 3.24M | 10.83M | 23.63M | 24.24M |
| Deferred Income Tax | 595K | (6.58M) | 0 | 0 | 0 |
| Stock-Based Compensation | 23.09M | 27.01M | 35.02M | 48.44M | 71.42M |
| Change in Working Capital | 16.98M | (21.05M) | (22.64M) | 22.59M | (19.72M) |
| Accounts Receivables | 0 | (20.73M) | (43.97M) | (11.43M) | (48.06M) |
| Inventory | (495K) | (3.45M) | (4.39M) | (3.17M) | (8.45M) |
| Accounts Payables | 22.66M | 7.64M | 30.78M | 40.31M | 50.1M |
| Other Working Capital | (5.18M) | (4.51M) | (5.05M) | (3.13M) | (13.32M) |
| Other Non-Cash Items | (90.41M) | 12.91M | 69.26M | 3.6M | 3.24M |
| Operating Cash Flow | (132.76M) | (120.14M) | (70.94M) | 10.33M | 55.83M |
| Capital Expenditures | (19.02M) | (278K) | (20.11M) | (993K) | (954K) |
| Acquisitions (Net) | (19M) | (7.98M) | (212.76M) | 0 | 0 |
| Purchases of Investments | (198.03M) | (132.32M) | (27.33M) | (89.03M) | (97.43M) |
| Sales of Investments | 157.6M | 140.3M | 153M | 19.89M | 74.43M |
| Other Investing Activities | 127M | 7.98M | (20M) | (20M) | 0 |
| Investing Cash Flow | 48.55M | 7.7M | (107.2M) | (90.13M) | (23.95M) |
| Debt Repayment | 0 | 0 | 305.3M | 0 | 0 |
| Common Stock Issued | 6.91M | 107.37M | 216.68M | 17.7M | 40.14M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 66.55M | 1.72M | (185.39M) | 0 | 0 |
| Financing Cash Flow | 73.47M | 109.09M | 336.6M | 17.7M | 40.14M |
| Effect of Forex Changes | (1K) | 12K | (133K) | (1.3M) | 3.22M |
| Net Change in Cash | (10.75M) | (3.34M) | 158.32M | (63.4M) | 75.24M |
| Free Cash Flow | (151.78M) | (120.41M) | (91.05M) | 9.33M | 54.87M |
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
Intrinsic Alpha fair value
Locked
Current Price
$92.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.